Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | INMT | O95050 | 3/20 | 0.38 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25002578 | 0.89 | TSHR (0.36) | CYP1A2CYP3A4CYP2C9CYP2C19RECQL | |
| SCHEMBL9482499 | 0.82 | ALDH1A1 (0.48) | CYP1A2CYP3A4CYP2C9CYP2C19RECQL | |
| SCHEMBL25001900 | 0.80 | ADRB1 (0.42) | CYP1A2CYP3A4CYP2C9CYP2C19RECQL | |
| SCHEMBL25002137 | 0.71 | INMT (0.32) | INMT | |
| SCHEMBL25001910 | 0.70 | GPR55 (0.40) | INMTMAPTALDH1A1 | |
| SCHEMBL25002906 | 0.67 | MEN1 (0.45) | CYP3A4INMTNPC1ALDH1A1 | |
| SCHEMBL4576513 | 0.67 | ADRB1 (0.36) | CYP2C9CYP2C19NOTUMSMN1; SMN2MAPT | |
| Timirdine SCHEMBL10799352 | 0.66 | ALDH1A1 (0.49) | CYP1A2CYP3A4CYP2C9CYP2C19INMT | |
| SCHEMBL25003074 | 0.66 | MEN1 (0.47) | CYP1A2CYP2C9CYP2C19INMTNOTUM | |
| SCHEMBL25001894 | 0.66 | GAA (0.38) | CYP1A2INMTNOTUMHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1699489-B1 | PHARMACEUTICAL COMPOSITION OF A SODIUM CHANNEL BLOCKER AND A SELECTIVE SEROTONIN UPTAKE INHIBITOR | KOCSIS PAL (HU) | 2013-02-13 | — | — | EP | disclosed |
| US-8048882-B2 | Pharmaceutical compositions with increased activity | RICHTER GODEON NYRT. (HU) | 2011-11-01 | — | — | US | disclosed |
| EP-1610785-B1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF SPASTICITY AND/OR PAIN | RICHTER GEDEON VEGYESZET (HU) | 2007-08-22 | — | — | EP | disclosed |
| US-20070129370-A1 | Novel pharmaceutical compositions with increased activity | RICHTER GODEON NYRT. (HU) | 2007-06-07 | — | — | US | disclosed |
| US-20070027143-A1 | Novel substituted 2,3-benzodiazepine derivatives | IVAX DRUG RESEARCH INSTITUTE, LTD. (HU) | 2007-02-01 | — | — | US | disclosed |
| EP-1699489-A2 | PHARMACEUTICAL COMPOSITION OF A SODIUM CHANNEL BLOCKER AND A SELECTIVE SEROTONIN UPTAKE INHIBITOR | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2006-09-13 | — | — | EP | disclosed |
| US-20060199841-A1 | Pharmaceutical combination for the treatment of spasticity and/or pain | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2006-09-07 | — | — | US | disclosed |
| EP-1610785-A2 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF SPASTICITY AND/OR PAIN | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 2006-01-04 | — | — | EP | disclosed |
| WO-2005058363-A2 | PHARMACEUTICAL COMPOSITION OF A SODIUM CHANNEL BLOCKER AND A SELECTIVE SEROTONIN UPTAKE INHIBITOR | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2005-06-30 | — | — | WO | disclosed |
| US-6858605-B2 | Substituted 2,3-benzodiazepine derivatives | IVAX DRUG RESEARCH INSTITUTE, LTD. (HU) | 2005-02-22 | — | — | US | disclosed |
| WO-2004089352-A2 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF SPASTICITY AND/OR PAIN | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2004-10-21 | — | — | WO | disclosed |
| US-20040152693-A1 | Novel substituted 2,3-benzodiazepine derivatives | IVAX DRUG RESEARCH INSTITUTE, LTD. | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152693-A1 | Novel substituted 2,3-benzodiazepine derivatives | GABRB2, GABRB3, GABRA2 | CYP1A2 55/4885CYP3A4 132/4885CYP2C9 252/4885 |
| US-20070027143-A1 | Novel substituted 2,3-benzodiazepine derivatives | GABRB2, GABRB3, GABRA2 | CYP1A2 55/4885CYP3A4 132/4885CYP2C9 252/4885 |
| US-20060199841-A1 | Pharmaceutical combination for the treatment of spasticity and/or pain | OPRM1, OPRL1, OPRD1 | CYP1A2 517/4885CYP3A4 1250/4885CYP2C9 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.